107 related articles for article (PubMed ID: 8527269)
1. Pharmacokinetic and pharmacodynamic analysis of a novel leukotriene biosynthesis inhibitor, MK-0591, in healthy volunteers.
Uematsu T; Kanamaru M; Kosuge K; Hara K; Uchiyama N; Takenaga N; Tanaka W; Friedman BS; Nakashima M
Br J Clin Pharmacol; 1995 Jul; 40(1):59-66. PubMed ID: 8527269
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic interaction between the lipoxygenase inhibitor MK-0591 and the cyclooxygenase inhibitor ibuprofen in man.
Depré M; Van Hecken A; Verbesselt R; De Lepeleire I; Schwartz J; Porras A; Larson P; Lin C; De Schepper PJ
Int J Clin Pharmacol Res; 1998; 18(2):53-61. PubMed ID: 9675622
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of multiple oral doses of MK-0591, a 5-lipoxygenase-activating protein inhibitor.
Depré M; Friedman B; Van Hecken A; de Lepeleire I; Tanaka W; Dallob A; Shingo S; Porras A; Lin C; de Schepper PJ
Clin Pharmacol Ther; 1994 Jul; 56(1):22-30. PubMed ID: 8033491
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the in vivo biochemical efficacy of orally active leukotriene biosynthesis inhibitors.
Tagari P; Brideau C; Chan C; Frenette R; Black C; Ford-Hutchinson A
Agents Actions; 1993 Sep; 40(1-2):62-71. PubMed ID: 8147271
[TBL] [Abstract][Full Text] [Related]
5. Blockade of leukotriene production by a single oral dose of MK-0591 in active ulcerative colitis.
Hillingsø J; Kjeldsen J; Laursen LS; Lauritsen K; von Spreckelsen S; Depré M; Friedman BS; Malmström K; Shingo S; Bukhave K
Clin Pharmacol Ther; 1995 Mar; 57(3):335-41. PubMed ID: 7697951
[TBL] [Abstract][Full Text] [Related]
6. Biochemical activity, pharmacokinetics, and tolerability of MK-886, a leukotriene biosynthesis inhibitor, in humans.
Depre M; Friedman B; Tanaka W; Van Hecken A; Buntinx A; DeSchepper PJ
Clin Pharmacol Ther; 1993 May; 53(5):602-7. PubMed ID: 8387904
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti-inflammatory 5-lipoxygenase-activating protein inhibitor.
Bain G; King CD; Schaab K; Rewolinski M; Norris V; Ambery C; Bentley J; Yamada M; Santini AM; van de Wetering de Rooij J; Stock N; Zunic J; Hutchinson JH; Evans JF
Br J Clin Pharmacol; 2013 Mar; 75(3):779-90. PubMed ID: 22803688
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)- indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor.
Brideau C; Chan C; Charleson S; Denis D; Evans JF; Ford-Hutchinson AW; Fortin R; Gillard JW; Guay J; Guévremont D
Can J Physiol Pharmacol; 1992 Jun; 70(6):799-807. PubMed ID: 1330258
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics and pharmacokinetics of AM103, a novel inhibitor of 5-lipoxygenase-activating protein (FLAP).
Bain G; King CD; Rewolinski M; Schaab K; Santini AM; Shapiro D; Moran M; van de Wetering de Rooij S; Roffel AF; Schuilenga-Hut P; Milne GL; Lorrain DS; Li Y; Arruda JM; Hutchinson JH; Prasit P; Evans JF
Clin Pharmacol Ther; 2010 Apr; 87(4):437-44. PubMed ID: 20182424
[TBL] [Abstract][Full Text] [Related]
10. Effect of FLAP antagonist MK-0591 on leukotriene production and ozone-induced airway responses in dogs.
Stevens WH; Lane CG; Woolley MJ; Ellis R; Tagari P; Black C; Ford-Hutchinson A; O'Byrne PM
J Appl Physiol (1985); 1994 Apr; 76(4):1583-8. PubMed ID: 8045835
[TBL] [Abstract][Full Text] [Related]
11. Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses.
Friedman BS; Bel EH; Buntinx A; Tanaka W; Han YH; Shingo S; Spector R; Sterk P
Am Rev Respir Dis; 1993 Apr; 147(4):839-44. PubMed ID: 8385430
[TBL] [Abstract][Full Text] [Related]
12. No pharmacokinetic or pharmacodynamic interaction between theophylline and the leukotriene biosynthesis inhibitor BAY x 1005.
Groen H; Moesker HL; Leeuwenkamp OR; Sollie FA; Jonkman JH
J Clin Pharmacol; 1996 Jul; 36(7):639-46. PubMed ID: 8844447
[TBL] [Abstract][Full Text] [Related]
13. Pharmacology of the 5-lipoxygenase inhibitors BAY Y 1015 and BAY X 1005 in the horse.
Cunningham FM; Andrews M; Landoni MF; Lees P
J Vet Pharmacol Ther; 1997 Aug; 20(4):296-307. PubMed ID: 9280370
[TBL] [Abstract][Full Text] [Related]
14. Antiasthmatic effects of a leukotriene biosynthesis inhibitor (MK-0591) in allergic dogs.
Becker AB; Black C; Lilley MK; Bajwa K; Ford-Hutchinson AW; Simons FE; Tagari P
J Appl Physiol (1985); 1995 Feb; 78(2):615-22. PubMed ID: 7759431
[TBL] [Abstract][Full Text] [Related]
15. Initial Clinical Experience with AZD5718, a Novel Once Daily Oral 5-Lipoxygenase Activating Protein Inhibitor.
Ericsson H; Nelander K; Lagerstrom-Fermer M; Balendran C; Bhat M; Chialda L; Gan LM; Heijer M; Kjaer M; Lambert J; Lindstedt EL; Forsberg GB; Whatling C; Skrtic S
Clin Transl Sci; 2018 May; 11(3):330-338. PubMed ID: 29517132
[TBL] [Abstract][Full Text] [Related]
16. Leukotrienes in ulcerative colitis: results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591.
Roberts WG; Simon TJ; Berlin RG; Haggitt RC; Snyder ES; Stenson WF; Hanauer SB; Reagan JE; Cagliola A; Tanaka WK; Simon S; Berger ML
Gastroenterology; 1997 Mar; 112(3):725-32. PubMed ID: 9041233
[TBL] [Abstract][Full Text] [Related]
17. Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients.
Hui KP; Taylor IK; Taylor GW; Rubin P; Kesterson J; Barnes NC; Barnes PJ
Thorax; 1991 Mar; 46(3):184-9. PubMed ID: 1851340
[TBL] [Abstract][Full Text] [Related]
18. Platelets, neutrophils, and vasoconstriction after arterial injury by angioplasty in pigs: effects of MK-886, a leukotriene biosynthesis inhibitor.
Provost P; Borgeat P; Merhi Y
Br J Pharmacol; 1998 Jan; 123(2):251-8. PubMed ID: 9489613
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of the leukotriene B4 receptor antagonist CP-105,696 in man following single oral administration.
Liston TE; Conklyn MJ; Houser J; Wilner KD; Johnson A; Apseloff G; Whitacre C; Showell HJ
Br J Clin Pharmacol; 1998 Feb; 45(2):115-21. PubMed ID: 9491823
[TBL] [Abstract][Full Text] [Related]
20. Single dose pharmacokinetics, safety and tolerability of MK-0476, a new leukotriene D4-receptor antagonist, in healthy volunteers.
Schoors DF; De Smet M; Reiss T; Margolskee D; Cheng H; Larson P; Amin R; Somers G
Br J Clin Pharmacol; 1995 Sep; 40(3):277-80. PubMed ID: 8527292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
